Metrodora Institute, a Leader in Treating Complex Conditions, Chooses
the Ivenix Infusion System From Fresenius Kabi
- LAKE ZURICH, Ill., June 29, 2023 — Fresenius Kabi announced today that its Ivenix Infusion System has been selected by the Metrodora Institute to meet the institute’s infusion medicine needs. The Metrodora Institute is an integrated, multidisciplinary medical and research center dedicated to treating neuroimmune axis disorders…..READ MORE
Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s
- Abide’s world-class discovery platform is focused on harnessing the therapeutic potential of one of the largest and most diverse enzyme classes – the serine hydrolases (SHs) – with the potential to deliver unprecedented compounds across a broad range of central nervous system (CNS) indications
- Abide’s lead product ABX 1431 is a first-in-class inhibitor of monoacylglycerol lipase (MGLL), modulating the endocannabinoid system. ABX-1431 is in clinical development for Tourette’s (exploratory phase IIa) and neuropathic pain (phase I)
- Lundbeck to acquire Abide for USD 250 million in upfront payment and with additional development and sales milestones
Valby, Denmark, San Diego, USA, 6 May 2019 – H. Lundbeck A/S (Lundbeck) and Abide Therapeutics, Inc. (Abide) today announced signing of a definitive agreement in which Lundbeck LLC has agreed to acquire Abide. Under the terms of the agreement, Lundbeck may pay USD 250 million (approximately DKK 1.65 billion) upfront with a commitment to pay future development and sales milestones to the group of current owners of up to USD 150 million (approximately DKK 1 billion). This acquisition provides Lundbeck a novel discovery platform and a U.S.-based research hub…READ MORE
AI Foundation Models – the Next Big Leap for Healthcare Predictive Analytics
According to the Kaiser Family Foundation, health expenditures in America totaled about $1.4 trillion in 2000. In 2022, these expenditures topped $4.5 trillion—a more than 340% jump. There are some obvious reasons for this: technological and pharmaceutical advances, an aging population, the prevalence of chronic diseases, unhealthy lifestyles, and even heightening regulatory requirements all play a part…. READ MORE
Teladoc Health Expands Obesity & Weight Management Capabilities
Personalized health and medical care program built to improve weight related care and reduce the chronic disease complications of obesity in a single integrated experience
PURCHASE, NY, March 07, 2024 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced expanded capabilities designed to help employers and health plans manage rising demand for anti-obesity medication such as glucagon-like peptide 1 (GLP-1) agonists and support safe, sustainable weight loss and cardiometabolic health improvement for members. New features include helping plan sponsors and pharmacy benefit managers manage and optimize the growing complexity and costs associated with obesity management, as well as care coordination with non-Teladoc Health physicians and lab testing. The multidisciplinary care model is designed by clinicians experienced in obesity medicine and delivered with a tailored approach to weight management.…READ MORE
Sapphire Digital, now part of Zelis, is a mission-driven company that drives competition in healthcare to lower cost and improve quality for all
Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2024 Annual Meeting
Berlin, Germany, and San Diego, CA, USA, April 3, 2023 – Bayer and Vividion Therapeutics, Inc. (Vividion) will present the latest research on their advancing oncology portfolio at the upcoming American Association for Cancer Research (AACR) 2024 Annual Meeting, taking place from April 5-10, 2024, in San Diego, California.…READ MORE
Privia Health Reports Third Quarter 2023 Financial Results; Announces New Market Entry in South Carolina
ARLINGTON, VA – November 3, 2023 – Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the third quarter and nine month periods ended September 30, 2023.
Third Quarter: Total revenue for the third quarter of 2023 was $417.3 million, compared to total revenue of $342.9 million for the prior year third quarter (+21.7%). Gross Profit for the third quarter of 2023 was $90.6 million, compared to $76.9 million for the prior year third quarter.